- Benzinga•4 months agoNovogen Licenses Phase II-ready Molecule from Genentech for Development in Glioblastoma for $5M Upfront , Plus Milestones
Novogen Ltd (NASDAQ: NVGN ) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group (OTC: RHHBY ), to develop and commercialise GDC-0084, a ...
- Benzinga•5 months ago
Novogen Ltd (NASDAQ: NVGN ) today announced that it had received confirmation from the United States Food and Drug Administration (FDA) that the Investigational New Drug (IND) application for Cantrixil ...
- PR Newswire•6 months agoNovogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer
NASDAQ: NVGN) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for Cantrixil (TRX-E-002-1) in ovarian cancer. The IND is a detailed regulatory filing which is required to initiate clinical studies in the United States.
NVGN : Summary for Novogen Limited - American Depo - Yahoo Finance
Novogen Limited (NVGN)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.69 x 100|
|Ask||2.39 x 800|
|Day's Range||1.70 - 1.77|
|52 Week Range||1.39 - 2.85|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|